FDA Regulation of Mobile Medical Apps

The latest communication from FDA regarding regulation of medical apps notes that mobile medical apps can greatly help patients be proactive and vigilant about their own healthcare. There has been increased demand for medical apps, and many of the apps depend on high levels of feedback between patients and clinicians. The FDA wants to regulate the apps efficiently, in a way that is tailored towards the risks and benefits of the apps.

If an app is intended to treat, diagnose, cure, mitigate, or prevent disease or other conditions, it will likely be considered a medical device subject to FDA regulation. Traditional hardware-based devices undergo change more slowly – and the traditional regulatory framework assessed moderate- and high-risk devices via a lengthy premarket review process. Software as a medical device (SaMD), on the other hand, is unique and constantly evolving.

The FDA responded to SaMD in 2011 with “Guidances with Digital Health Content” and some deregulation. The FDA has continued to oversee SaMD (including mobile medical apps), and recently the International Medical Device Regulators Forum (IMDRF) have established a framework for efficient SaMD review that meets patient and developers’ needs. In 2017, the FDA guidance document, Digital Health Innovation Action Plan, described the agency’s plan for a new regulatory model for digital health technologies consistent with the IMDRF policies – including the precertification program for developers to be assessed for quality in order to qualify for streamlined or no premarket review.

An SaMD manufacturer who is certified to have high quality software design, testing, and other internal quality processes, will truly benefit from the pre-certification program. Low-risk products may not undergo premarket review, and high-risk products would be efficiently reviewed. Plus, post-market data collection on the safety and effectiveness of the device would be streamlined, which ultimately benefits the consumers who demand quality mobile medical apps.

FDA Regulation of Mobile Medical Apps by Jeffrey Shuren, MD, JD; Bakul Patel, MS, MBA; Scott Gottlieb, MD

About the author

Amy enjoys researching and writing about developments in medical technology and how that intersects with US law. She received her J.D. from the University of Florida Levin College of Law in 2020 and now works as a Regulatory Associate for SoftwareCPR®, a general-purpose regulatory consulting firm that is recognized globally for their expertise with standards and national regulations pertaining to medical device, mobile medical app, and HealthIT software.

SoftwareCPR Training Courses:

IEC 62304 and other emerging standards for Medical Device and HealthIT Software

Our flagship course for preparing regulatory, quality, engineering, operations, and others for the activities and documentation expected for IEC 62304 conformance and for FDA expectations. The goal is to educate on the intent and purpose so that the participants are able to make informed decisions in the future.  Focus is not simply what the standard says, but what is meant and discuss examples and approaches one might implement to comply.  Special deep discount pricing available to FDA attendees and other regulators.

3-days onsite with group exercises, quizzes, examples, Q&A.

Instructor: Brian Pate

Next public offering:  TBD

Email training@softwarecpr.com to request a special pre-registration discount.  Limited number of pre-registration coupons.

Registration Link:

TBD

 


 

Being Agile & Yet Compliant (Public or Private)

Our SoftwareCPR unique approach to incorporating agile and lean engineering to your medical device software process training course is now open for scheduling!

  • Agile principles that align well with medical
  • Backlog management
  • Agile risk management
  • Incremental and iterative software development lifecycle management
  •  Frequent release management
  • And more!

2-days onsite (4 days virtual) with group exercises, quizzes, examples, Q&A.

Instructors: Mike Russell, Ron Baerg

Next public offering: March 7 & 28, 2024

Virtual via Zoom

Registration Link:

Register Now

 


 

Medical Device Cybersecurity (Public or Private)

This course takes a deep dive into the US FDA expectations for cybersecurity activities in the product development process with central focus on the cybersecurity risk analysis process. Overall approach will be tied to relevant standards and FDA guidance documentation. The course will follow the ISO 14971:2019 framework for overall structure but utilize IEC 62304, IEC 81001-5-1, and AAMI TIR57 for specific details regarding cybersecurity planning, risk characterization, threat modeling, and control strategies.

2-days onsite with group exercises, quizzes, examples, Q&A.

Instructor: Dr Peter Rech, 2nd instructor (optional)

Next public offering:  TBD

Corporate Office

15148 Springview St.
Tampa, FL 33624
USA
+1-781-721-2921
Partners located in the US (CA, FL, MA, MN, TX) and Canada.